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Abstract 
Background and Objectives: The RANKL-OPG bi-molecular system is the “bottle-
neck” regulator of osteoclastogenesis and bone resorption, both in physiological and 
pathological conditions. This review aims to elaborate the current knowledge on 
RANKL and OPG in periodontal disease, and evaluate their diagnostic and prognostic 
potential as biomarkers of the disease. 
Materials and Methods: To pursue this aim, electronic and manual searches were 
performed for identifying clinical and in vivo studies on RANKL and OPG in gingival 
tissue, gingival crevicular fluid, saliva and blood. Smoking and diabetes mellitus were 
also considered for their potential effects. 
Results: Papers fulfilling the inclusion criteria demonstrate that RANKL is up-
regulated, whereas OPG is down-regulated in periodontitis, compared to periodontal 
health, resulting in an increased RANKL/OPG ratio. This ratio is further up-regulated 
in smokers and diabetics, and is not affected by conventional periodontal treatment.  
Conclusions: The increased RANKL/OPG ratio may serve as a biomarker that 
denotes the occurrence of periodontitis, but may not necessarily predict on-going 
disease activity. Its steadily elevated levels post-treatment may indicate that the 
molecular mechanisms of bone resorption are still active, holding an imminent risk 
for relapse of the disease. Additional adjunct treatment modalities that would “switch-
off” the RANKL/OPG ratio may therefore be required. 
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Introduction 
Bone is a dynamic tissue hard tissue that is subjected to continuous remodelling, in 
order to meet the functional adaptation needs. The remodelling process is 
characterised by coupling of resorption of the bone matrix by osteoclasts, and its re-
formation by osteoblasts. The alveolar bone of the periodontium is no exception to 
this process. Remodelling of the alveolar bone can occur in physiological situations, 
such as occlusal forces, tooth eruption, clinical interventions, such as orthodontic 
tooth movement, and pathological conditions, such as periodontitis and periapical 
pathoses. Under physiological conditions, a dynamic balance is established between 
bone formation and resorption. However, if the balance switches towards enhanced 
bone resorption, then bone destructive pathology will occur (Lerner 2004). 
The long-sought molecular mechanisms behind the cell-to-cell interaction that 
regulate bone resorption were elucidated in the late 1990s. Receptor Activator of 
Nuclear Factor-κB Ligand (RANKL), a member of the Tumor Necrosis Factor (TNF) 
ligand superfamily, was identified as a cell membrane-bound factor responsible for 
stimulation of osteoclast differentiation and bone resoprtion (Kong et al. 1999; Lacey 
et al. 1998). RANKL is produced as a membrane-bound or secreted ligand by 
osteoblasts, fibroblasts, or activated T- and B-cells. Of note, three isoforms of 
RANKL have been identified (Ikeda et al. 2001), which can potentially multimerize 
(Ikeda et al. 2003): RANKL1 possesses an intracellular, transmembrane and 
extracellular domain, RANKL2 has a shorter intracellular domain, and RANKL3 
lacks both the intracellular and transmembrane domain, and is thought to act as 
soluble ligand. These three different variants may have different roles or potencies in 
the regulation of osteoclastogenesis, with RANKL1 being the predominant inducer, 
whereas RANKL3 a potential attenuator (Suzuki et al. 2004).  
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By activating its cognate RANK receptor on the surface of pre-osteoclasts, it 
triggers their fusion and differentiation into mature osteoclasts, thus activating bone 
resorption (Teitelbaum et al. 2003). The action of RANKL can be blocked by its 
soluble decoy receptor osteoprotegerin (OPG), which is a member of the TNF 
receptor superfamily, with structural homology to RANK (Simonet et al. 1997). By 
binding to RANKL, OPG prevents its further interaction with RANK, and 
subsequently all the down-stream molecular events that lead to osteoclast 
differentiation and bone resorption. A simplified diagrammatic representation of the 
RANKL-RANK-OPG interplay is provided in the Figure. The production of RANKL 
and OPG by various cells types is controlled by systemic and local stimuli, including 
hormones, inflammatory mediators and bacterial products (Lerner 2006; Liu et al. 
2010).  
Increased RANKL or decreased OPG local expression can cause bone 
resorption at various sites of the human skeleton. Conversely, decreased RANKL or 
increased OPG expression could result in enhanced bone formation, leading to 
osteopetrotic conditions. The involvement of the RANKL-OPG system is well 
established in the pathogenesis of diseases of bone and mineral metabolism, such as 
rheumatoid arthritis, postmenopausal osteoporosis, Paget´s disease, and bone 
malignancies, such as multiple myeloma (Vega et al. 2007). Among various 
biomarkers of bone destruction, the investigation of RANKL and OPG in biological 
analytes of relevance may deliver reliable information on the state of periodontal 
disease, but may not be able to predict future activity (Buduneli et al. 2011). This 
paper provides a review of the current literature, elaborating in more detail the 
findings specifically on the RANKL-OPG system, with regards to periodontal 
diseases. 
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Materials and Methods 
Search and selection strategy 
A literature search was performed using the U.S. National Institutes of Health 
PubMed database since August 2011, by employing the following search terms: 
“periodontitis’’ OR “periodontal disease(s)” AND “RANKL” OR “OPGL” OR 
“OPG” AND “gene expression” OR “mRNA expression” OR “protein expression” 
OR “gingival crevicular fluid” OR “saliva” OR “serum” OR “plasma” The search was 
limited to the English language. After screening of the titles and abstracts, the full text 
of publications was obtained for the selected articles. Original research papers were 
considered, including both clinical studies in human populations (cross-sectional or 
longitudinal) and in vivo experimental periodontitis studies in animal models. In vitro 
studies were considered when necessary, for instance, on the description of the 
biology of the RANKL-OPG system. A further sub-classification of the studies was 
based on the association of the RANKL-OPG system with active lesions, periodontal 
microbiota, other markers of bone resorption, diabetes mellitus, smoking, 
osteoporosis and periodontal treatment. 
 
Review of Current Literature 
 
Cell sources of RANKL and OPG in periodontal tissues 
In order to understand the roles of RANKL and OPG in the pathophysiology of 
periodontal disease, their cell sources need to be identified. The present knowledge on 
this topic largely derives from in vitro or in vivo studies. Under physiological 
conditions, RANKL in the periodontium is expressed by mesenchymal cells, 
primarily osteoblasts and PDL cells (Kajiya et al. 2010). The expression of RANKL is 
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of physiological relevance for the adaptation of the periodontium to occlusal forces, 
during tooth eruption (Wise et al. 2000), or during orthodontic tooth movement 
(Garlet et al. 2008; Garlet et al. 2007). In the healthy periodontium, OPG is 
continually produced by resident periodontal connective tissue fibroblasts and 
potentially endothelial cells (Kobayashi-Sakamoto et al. 2004), but not epithelial cells 
(Sakata et al. 1999), or T-cells (Belibasakis et al. 2011c; Kawai et al. 2006).  
The primary source of RANKL in periodontal disease is Th1 or Th17 cells, as 
well as B-cells (Han et al. 2006; Han et al. 2009; Kawai et al. 2006; Vernal et al. 
2006). Nevertheless, all resident mesenchymal cells may also express RANKL under 
bacterial challenge (Belibasakis et al. 2007; Kajiya et al. 2010). Interestingly, T-
regulatory cells can attenuate RANKL expression by other activated T-cells (Ernst et 
al. 2007). OPG production in disease presumably derives by the same cells as in 
health. 
 
Localization and expression of RANKL and OPG in gingival tissues 
An early indication that RANKL and OPG could be of relevance to the periodontium 
came from in vitro work demonstrating that periodontal ligament cells do produce 
RANKL and OPG and they can as well support osteoclastogenesis through RANKL 
signalling (Kanzaki et al. 2001). Early in vivo studies also demonstrated a functional 
role of RANKL-producing activated T-cells in Aggregatibacter 
actinomycetemcomitans periodontitis models (Taubman et al. 2001; Teng 2002; Teng 
et al. 2000).  
Clearer indications of the involvement of the RANKL-OPG system in 
periodontal disease came with studies investigating the expression and localization of 
these molecules in healthy and diseased human gingival tissue. Immunohistochemical 
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studies demonstrated significantly higher RANKL and lower OPG staining in 
periodontitis-affected tissue, compared to healthy gingival tissue (Crotti et al. 2003). 
Positive staining for RANKL protein was associated primarily with CD3+ 
lymphocytes (approximately 30% of these cells), whereas weaker staining was 
detected in the extracellular connective tissue. Fewer CD3+ cells were associated with 
non-periodontitis tissues. OPG staining was associated with endothelial cells, in both 
health and disease (Crotti et al. 2003). RANKL-positive lymphocytes are more 
densely distributed in the inflammatory connective tissue zone of diseased gingival 
tissue (Lu et al. 2006). Accordingly, in situ hybridization studies show that high levels 
of RANKL-specific mRNA transcripts are localized in inflammatory cells, mainly 
lymphocytes (Liu et al. 2003).  
These findings are further backed by gene expression studies using 
quantitative real time Polymerase Chain Reaction (qPCR) to investigate RANKL and 
OPG transcripts in human gingival tissue biopsies (Bostanci et al. 2007b; Garlet et al. 
2004; Honda et al. 2006). The rate of detection for RANKL expression is reported at 
0-40% in health, 25-80% in gingivitis, 54-100% in Chronic Periodontitis (CP) and 75-
100% in Aggressive Periodontitis (AP), whereas for OPG these rates are 70-100% in 
health and 100 % in all three forms of the disease (Belibasakis et al. 2011a; Bostanci 
et al. 2007b; Garlet et al. 2004). In a study employing semi-quantitative reverse-
transcription PCR, the detection rates of RANKL and OPG are reported to be 100% in 
both health and CP (Wara-aswapati et al. 2007). 
With regards to expression levels, RANKL is reportedly 2.7-15.8-fold higher 
in CP than in health, when detectable (Belibasakis et al. 2011a; Cesar-Neto et al. 
2007; Wara-aswapati et al. 2007), and 1.7-3.0-fold higher in CP than gingivitis 
(Belibasakis et al. 2011a; Bostanci et al. 2007b; Honda et al. 2006). However, the 
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comparison of RANKL expression levels between CP and AP yielded conflicting 
results, ranging from no differences (Garlet et al. 2004) to 10-fold higher expression 
in AP (Bostanci et al. 2007b). Accordingly, OPG expression was shown to be either 
higher in CP than in AP (Garlet et al. 2004), or 16-fold lower in CP, than AP 
(Bostanci et al. 2007b). In comparison to health, lower OPG expression levels were 
reported in CP, at a range of 0.2-16-fold (Bostanci et al. 2007b; Cesar-Neto et al. 
2007; Wara-aswapati et al. 2007). Such discrepancies may reflect the episodic nature 
of periodontitis and highlight the technical challenge of sampling while capturing 
ongoing disease activity.  
Collectively, these findings denote higher RANKL and lower OPG expression 
levels in periodontitis, compared to health or gingivitis, in line with the established 
biological role of these molecules in bone resorption. Two of the studies have also 
taken into account the RANKL/OPG ratio, demonstrating a 2.2-fold increase in CP 
compared to health (detectable levels) (Wara-aswapati et al. 2007) or equally elevated 
levels in CP and AP, compared to health or gingivitis (Bostanci et al. 2007b). These 
findings warrant further investigation of this measure as a potential biomolecular 
marker of periodontitis.  
 
Detection and levels of RANKL and OPG in gingival crevicular fluid (GCF) 
Studies on gene expression and tissue localization of RANKL and OPG provided 
tangible evidence that RANKL and OPG are involved in periodontal health and 
disease. Nevertheless, despite their experimental value, such approaches cannot 
feasibly assist the diagnosis of periodontal status due to their invasive nature (i.e. a 
tissue biopsy is required). A promising auxiliary diagnostic approach in Clinical 
Periodontology is the non-invasive sampling of GCF, the window to the periodontium  
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(Uitto 2003). A number of pro-inflammatory markers have been detected in this 
inflammatory exudate (Lamster et al. 2007), which would provide a rational basis for 
investigating RANKL and OPG as well. Indeed, Mogi and co-workers were the first 
to demonstrate that RANKL and OPG are detectable in GCF by conventional 
enzyme-linked immunosorbent assay (ELISA) (Mogi et al. 2004). RANKL was 
detected in only 1/28 healthy sites, but was readily detectable in CP, irrespective of 
the severity. In fact, it appears that RANKL concentrations were higher when the 
severity was milder (ap. 180 pg/µl), but decreased at a moderate or severe stage (ap. 
30 pg/µl). The reverse was the case for OPG, which was detected at higher levels in 
health (ap. 400 pg/µl), but was 3-4-fold lower in CP, irrespective of disease severity. 
Accordingly, the RANKL/OPG ratio was elevated in CP compared to health, while 
this also proved to be 50% higher in mild, compared to moderate or severe disease 
(Mogi et al. 2004). These findings were followed up in further studies. The frequency 
of detection of RANKL in health and CP, was reported at 33% and 100% (Bostanci et 
al. 2007a), 46% and 85% (Vernal et al. 2004), and 93% and 100% (Lu et al. 2006), 
respectively. In all cases, the RANKL concentrations or total amounts were higher in 
CP than in health. OPG was detected at a frequency of 100% in both healthy and CP 
samples (Bostanci et al. 2007a). However, another study reports OPG detection 
frequency of 0% in healthy sites of healthy subjects, 75% in healthy sites of subjects 
with CP, and 72% in diseased sites of patients with CP (Lu et al. 2006). It is not clear 
if such discrepancies account for intra-individual differences between study 
populations, or are a result of methodological variations. In gingivitis, a low 
frequency of RANKL detection was revealed (41%), with concentration levels similar 
to health (below 10 pg/µl) (Bostanci et al. 2007a). When the RANKL/OPG ratio was 
considered, a clear increase is detected in periodontitis compared to health or 
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gingivitis, but no differences are detected between CP and AP, narrowing down to the 
conclusion that the RANKL/OPG ratio could be a good indicator of the occurrence of 
periodontitis (Kinane et al. 2011; Taubman et al. 2007). An analytical summary of 
various studies investigating RANKL and OPG concentrations in GCF, as well as 
their relative ratio in health, gingivitis, CP and AP is provided in the Table. It should 
be noted, that the available studies do not take under consideration the possibility that 
RANKL may exist in different isoforms, and rarely consider that it may occur in a 
molecular complex with OPG. In the available methodologies (primarily ELISA), the 
detection antibodies may not necessarily be suitable for the detection of all three 
RANKL isoforms, making difficult the evaluation of their physiological or 
pathological relevance in GCF.  
A more complex point that warrants further investigation is the association of 
RANKL and OPG to clinical measures of periodontal disease. There are discrepancies 
between studies, indicating that RANKL or the RANKL/OPG ratio correlates 
negatively (Mogi et al. 2004), positively (Bostanci et al. 2007a; Vernal et al. 2004) or 
not at all (Lu et al. 2006) with disease severity. Still, there appears to be no correlation 
between RANKL/OPG ratio in GCF and gingival inflammation (Bostanci et al. 
2007a; Mogi et al. 2004), which may indicate that this measure shows some 
specificity for the occurrence of periodontal bone destruction, hence periodontitis, 
rather than constituting a “conventional” or “classical” marker of periodontal 
inflammation.  
 
Association of RANKL and OPG with active periodontal lesions 
A rather obscure issue is the association of the RANKL-OPG system with disease 
activity at different periodontal sites, which may explain the previously mentioned 
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discrepancies between clinical measurements and the RANKL/OPG ratio. Most of the 
studies in the field are of cross-sectional nature and have not taken under 
consideration the disease progression status of the periodontal sites. Progressive tissue 
destruction can be assessed by the tolerance method, whereby active sites are 
determined as the ones that exhibit attachment loss > 2.0 mm during the following 2-
month period (Haffajee et al. 1983). The few studies that employed this approach 
indicate that active CP sites exhibit higher RANKL tissue expression by 3.4-fold 
(Dutzan et al. 2009) and GCF concentrations by 18% (Silva et al. 2008; Vernal et al. 
2004), than inactive ones. The collective conclusion from these studies is that episodic 
attachment loss is associated with higher RANKL levels than disease remission. 
However, these studies have not considered the investigation of OPG, which would 
have allowed for a broader monitoring of the RANKL/OPG ratio during active 
periodontal disease. Hence, conclusions on the association of the RANKL-OPG 
system with disease activity may still be preliminary. 
 
RANKL and OPG levels in saliva 
A number of studies have investigated the presence and levels of RANKL and OPG in 
whole un-stimulated saliva, in an attempt to determine their potential use as salivary 
biomarkers of periodontal disease. In one of the first studies, salivary RANKL 
concentration was below detection limits (0.375 pmol/L) in 81% of the subjects 
irrespective of their healthy or CP status, whereas TNF-α was detected in all subjects 
was significantly higher in subjects with CP (4.33 pg/ml), compared to healthy ones 
(2.03 pg/ml) (Frodge et al. 2008). Other studies in saliva detected RANKL 
concentration at a range of 20-200 pg/ml (Buduneli et al. 2008), or 60-110 pg/ml (El-
Sharkawy et al. 2010), and OPG at a range of 40-250 pg/ml (Buduneli et al. 2008), in 
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various subject groups. Still, the available literature is rather limited to deduce secure 
conclusions on the diagnostic value of RANKL and OPG in saliva.  
 
Association of RANKL and OPG with periodontal microbiota 
As oral bacteria are the etiological factor of periodontal diseases, it is rational to 
postulate that putative periodontal pathogens would be important determinants of 
RANKL and OPG regulation in periodontal tissues. To this extent, species associated 
with subgingival biofilms can more potently up-regulate the RANKL/OPG ratio, 
compared to supragingival biofilms in vitro (Belibasakis et al. 2011b). Clinically, the 
presence of Porphyromonas gingivalis in subgingival biofilms at CP sites, positively 
correlates (r = 0.64) with RANKL tissue gene expression levels or the RANKL/OPG 
ratio (r = 0.67), but not with OPG (r = -0.24) (Wara-aswapati et al. 2007). 
Accordingly, a positive correlation is found between RANKL total amounts in GCF 
and the subgingival presence of P. gingivalis and Treponema denticola in CP 
(p<0.05, no r correlation coefficient reported), but no microbial correlations are found 
in healthy individuals (Sakellari et al. 2008). The association between microbiota and 
the RANKL/OPG ratio certainly warrants further investigation, to determine if 
specific bacterial species are more highly implicated in periodontal bone destruction 
than others. This may enable the design of more targeted therapeutic approaches, 
aiming at microbial-specific reduction or elimination. 
 
Association of RANKL and OPG with other markers of bone resorption 
The activation of osteoclast precursors by RANKL through RANK receptor triggers 
several intracellular events that eventually lead to their differentiation into multi-
nucleated osteoclasts. Nuclear Factor of Activated T-cells, cytoplasmic 1 (NFATc1) is 
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the master transcription factor for osteoclastogenesis down-stream the RANKL-
RANK signalling, responsible for activating most genes of osteoclast-specific 
function (Takayanagi 2007; Takayanagi et al. 2002). NFATc1 gingival tissue gene 
expression is higher in periodontitis, compared to gingivitis or health, showing a 
strong positive correlation (r = 0.846) with RANKL expression (Belibasakis et al. 
2011a). Although this finding may potentially denote on-going osteoclast 
differentiation in the periodontium, it is also possible that NFATc1 expression 
accounts for RANKL-expressing activated T-cells. To this extent, the expression of 
dendritic cell-specific transmembrane protein (DC-STAMP), which is involved in 
osteoclast fusion and multi-nucleation, was also investigated. It was found that DC-
STAMP was only sparsely detected in these tissues (0% in health, 20% in gingivitis, 
11% in CP and 15% in AP), which may denote a limited number of osteoclast fusion 
events at the time of sample collection. Hence, the cellular source of NFATc1 in the 
periodontium awaits further clarification. 
Cathepsin-K is a major cysteine proteinase of the osteoclasts, responsible for 
hydrolysing extracellular bone matrix proteins, upon dissolution of the inorganic 
matrix by acid secretion (Teitelbaum 2000). Hence, as an end product of osteoclast 
function, Cathepsin-K is a candidate marker of on-going periodontal bone destruction. 
To this extent, Cathepsin-K was not detected in GCF from healthy subjects, but was 
found in increased concentrations in GCF from patients with CP, irrespective of 
disease severity. A positive correlation (r = 0.726) with RANKL concentrations was 
also revealed (Mogi et al. 2007). This finding could provide clinical justification of 
the molecular events activated in the osteoclast by RANKL. 
Tumor necrosis factor-α-converting enzyme (TACE) is a metalloprotease that 
can shed and release several cytokines from the cell membrane, thus propagating their 
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pro-inflammatory or growth effects (Black et al. 1997). Interestingly, compared to 
several other “sheddases”, TACE has shown the highest specificity for cleaving and 
releasing RANKL (Lum et al. 1999). TACE total amounts and concentrations were 
studied in GCF, demonstrating equally higher levels in CP and AP, compared to 
health or gingivitis, as well as a positive correlation (r = 0.243) with RANKL levels 
(Bostanci et al. 2008). In another study, TACE protein levels were measured in 
gingival tissues (by Western blot), as well as GCF (by ELISA). Compared to health, a 
similar trend of elevated TACE levels was observed in both gingival tissue and GCF 
(respectively: 1.7-fold in gingivitis, 2.6- and 1.8-fold in moderate CP, 2.3- and 1.5-
fold in severe CP) (Lee et al. 2011). By studying a group of CP patients who were 
under treatment with immunosuppressants, it was also deduced that T-cells are the 
likely source of this enzyme in the diseased periodontium (Bostanci et al. 2008). 
Reduction of TACE levels or inhibition of its activity may therefore be of interest for 
future adjunct therapeutic approaches.  
 
Association of RANKL and OPG with smoking 
Since smoking is a major risk factor in the development of periodontal disease  
(Johnson et al. 2007), a number of studies have addressed the additive effect of 
smoking on the regulation of the RANKL-OPG system, in CP. Interestingly, 
compared to their matched controls, smokers with CP exhibit lower OPG 
concentrations in serum (Lappin et al. 2007; Ozcaka et al. 2010), and higher RANKL 
but lower OPG concentrations in whole saliva (Buduneli et al. 2008), both resulting in 
enhanced RANKL/OPG ratio. Accordingly, by using qPCR it was found gingival 
tissue OPG gene expression was 1.4-fold lower, whereas the RANKL/OPG ratio was 
1.6-fold higher in smokers than non-smokers with CP (Cesar-Neto et al. 2007). When 
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the effect of smoking on RANKL and OPG was studied in GCF, there were no 
differences between former smokers and current smokers with CP. However, OPG 
concentration and the RANKL/OPG ratio decreased in GCF, when a threshold of 20 
pack-years was taken under consideration (Tang et al. 2009). Hence, increased 
lifetime exposure to smoking could suppress OPG production, resulting in increased 
RANKL/OPG expression ratio. This may not be surprising given the important 
histopathological changes of gingival connective tissue in smokers, as the cells of this 
tissue are the major producers of OPG in the healthy periodontium. Collectively, these 
findings provide evidence that smoking can indeed affect the RANKL-OPG system in 
a manner that would further enhance bone loss in periodontitis. 
 
Association of RANKL and OPG with osteoporosis 
Osteoporosis is a disease of bone metabolism that could potentially have an impact on 
the development of periodontal disease (Lerner 2006). In vivo studies in experimental 
(ligature-induced) periodontitis, demonstrated that osteoporotic rats exhibit more 
severe histopathological tissue breakdown and higher proportions of RANKL-positive 
cells, than non-osteoporotic ones (Allam et al. 2010). On the clinical aspect, 
osteoporotic subjects with CP exhibit higher RANKL and OPG plasma concentrations 
that matched periodontally-healthy subjects (Jabbar et al. 2011), although there appear 
to be no differences in their relative RANKL/OPG ratio. Nevertheless, further studies 
with stringent periodontal diagnosis, which would also involve GCF measurements, 
would shed more light on the interplay between the RANKL-OPG system and 
osteoporosis, in periodontitis. 
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Association of RANKL and OPG with diabetes mellitus 
Diabetes mellitus is an endocrine disorder that constitutes a major systemic risk factor 
for periodontal disease (Lamster et al. 2008). Diabetics exhibit higher plasma OPG 
concentrations and lower RANKL/OPG ratio compared to non-diabetics, and 
periodontal status does not significantly affect this (Lappin et al. 2009). However, 
diabetes mellitus appears to be an important factor affecting the RANKL/OPG ratio 
locally in the periodontium. A recent study using semi-quantitative PCR investigated 
gingival tissue gene expression in patients with CP, and reported that the diabetic 
status did not considerably affect RANKL expression, whereas there was a trend 
towards down-regulation of OPG expression, compared to matched non-diabetics 
(Duarte et al. 2011). Further studies analysing GCF demonstrate that RANKL 
concentration and the RANKL/OPG ratio are higher in poorly-controlled diabetics 
with CP, than in well controlled diabetics, or non-diabetics, with matched periodontal 
status (Ribeiro et al. 2011; Santos et al. 2010), and this ratio is barely affected by 
periodontal therapy (Santos et al. 2010). Hence, it appears that the RANKL/OPG ratio 
is negatively influenced in diabetes mellitus, particularly by poor glycemic control. 
 
Effect of periodontal treatment on the RANKL-OPG system 
The role of the RANKL-OPG system is therefore well documented in periodontal 
disease, reflected by an increased RANKL/OPG ratio, which could be a good 
indicator of molecular diagnostic value for the disease. However, the remaining 
question is if periodontal treatment can in fact reduce this ratio to the levels of health, 
and thus provide a good predictive value for the treatment of the disease. The few 
available studies employing the initial non-surgical phase of periodontal therapy 
(including oral hygiene instructions and scaling and root planing) demonstrate that 
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this may not be the case. Gingival tissue RANKL and OPG gene expressions were 
evaluated by semi-quantitative PCR, in a cohort of CP subjects that received 
periodontal surgery 4-6 weeks after the initial phase of periodontal treatment. It was 
found that both genes were expressed at lower levels than in tissues from healthy 
control sites (undergoing crown-lengthening procedures), but with no significant 
differences in the RANKL/OPG ratio (Dereka et al. 2010). Despite the inclusion of 
healthy controls in that study, it is difficult to drive conclusions on the effect of initial 
periodontal treatment from the reported data, as samples could not be taken from the 
actual diseased sites in advance of the therapy. This highlights the ethical and 
technical limitations of invasive tissue sampling in prospective studies. 
Further on, studies have investigated the effect of periodontal treatment on the 
RANKL-OPG system in GCF. In an earlier study, the analysis of GCF following 
initial periodontal treatment indicated no changes in RANKL but a decrease in OPG, 
with a potential increase in the RANKL/OPG ratio after 4 weeks. In addition, no 
differential responses were observed between smokers and non-smokers (Buduneli et 
al. 2009). Accordingly, initial periodontal treatment caused a transient reduction of 
the RANKL/OPG ratio in well controlled diabetics, compared to baseline or poorly 
controlled diabetics, which, however, resumed baseline levels after 6 months of 
treatment (Santos et al. 2010). In a recent study employing a cohort of CP and AP 
patients, initial periodontal treatment did not affect the RANKL/OPG ratio in either 
group up-to 4 months of monitoring, despite the improved clinical outcome (Bostanci 
et al. 2011).  
Collectively, these studies indicate that despite its potential value as a 
biomarker for untreated periodontitis, the RANKL/OPG ratio may not be a suitable 
predictor of clinically successful treatment outcome. It may also denote that the 
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molecular mechanisms of bone resorption are still active, and thus the corresponding 
periodontal sites can be potentially at a risk of further disease relapse.  
 
Effects of experimental adjunct periodontal treatment modalities on the 
RANKL-OPG system 
The increased RANKL/OPG ratio following initial periodontal therapy may warrant 
additional adjunctive treatment modalities. Some of them have been tested in 
experimental periodontitis models, as for their improved efficiency in clinical 
outcomes. The inhibition-by-OPG approach has been used in one of the first in vivo 
studies to demonstrate the role of the RANKL-OPG system in experimental 
periodontitis (Teng et al. 2000). In this T-cell specific A. actinomycetemcomitans-
induced periodontitis model in mice, concomitant administration OPG diminished 
alveolar bone destruction and reduced osteoclast numbers in the periodontium. In a 
later study using a ligature-induced periodontitis model in rats, subcutaneous co-
administration of OPG-tagged-Fc resulted in preserved alveolar bone volume and 
reduced osteoclast number on the alveolar crest surface (Jin et al. 2007). These 
findings imply that the “natural” inhibition of RANKL by OPG could confer a 
therapeutic benefit in the prevention of alveolar bone resorption in periodontitis. 
The effects of an anti-RANKL antibody on periodontal bone resorption were 
tested in vivo in a T-cell specific A. actinomycetemcomitans-induced periodontitis 
model. Local (palatal) co-administration of a rabbit anti-RANKL IgG, resulted in 
inhibition of bone resorption and osteoclast formation on the alveolar bone surface, 
and decreased RANKL concentrations in gingiva, proposing an immunological 
approach to ameliorate periodontitis (Lin et al. 2011). 
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In an earlier study using a similar A. actinomycetemcomitans-induced 
periodontitis model, the potassium channel blocker kaliotoxin was systemically 
administered to rats. This abrogated bone resorption by 84 %, along with a decrease in 
RANKL mRNA expression by T-cells in the gingival tissue, proposing an 
interventional strategy for prevention or inhibition of alveolar bone loss (Valverde et 
al. 2004). 
In a recent clinical study, a dietary approach was employed: CP patients 
received initial periodontal treatment and a combination of omega-3 fatty acids and 
aspirin, or placebo, for up-to 6 months. The test group exhibited a reduction of 
RANKL concentrations in saliva and a greater improvement of clinical parameters, 
compared to the placebo group, proposing a sustainable, low-cost intervention to 
augment periodontal therapy (El-Sharkawy et al. 2010). 
 
Discussion and Conclusion 
All the available studies collectively indicate that both RANKL and OPG can be 
detected in gingival tissue and biological fluids, including GCF, saliva and serum. 
RANKL is increased whereas OPG is decreased in periodontitis compared to health, 
or gingivitis. These regulations are well represented by the increased RANKL/OPG 
ratio, indicative of the occurrence of periodontitis. However, the RANKL/OPG ratio 
is not reduced or “switched-off” following a clinically successful initial periodontal 
treatment outcome. Therefore, this ratio may have a potential value as a biomarker for 
untreated periodontitis, or denote prior history of the disease at the site level, but it 
may not be a suitable predictor of clinically successful treatment outcome. 
Importantly, an increased RANKL/OPG ratio may also denote that the molecular 
mechanisms of bone resorption are still active, and that the corresponding periodontal 
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sites are still at a potential risk of further relapse at a future time-point. This flags-up 
the need for consideration of additional (immuno-) modulatory therapies targeting the 
RANKL-OPG-specific host responses in the long-term management of periodontal 
diseases, in line with the concept of Taubman and co-workers (Taubman et al. 2007). 
So how could we use the RANKL/OPG ratio further? What do we need to do 
in order to more efficiently define if it can be of predictive value for on-going disease 
activity, or an indicator of higher risk for further disease progression? Rather than the 
available cross-sectional studies, longitudinal prospective studies will be required, in 
order to monitor concomitantly clinical disease progression and the levels of the 
RANKL/OPG ratio. Interventional studies will also be needed, utilizing adjunctive 
treatments and monitoring again changes in this ratio, to determine if its reduction is 
commensurate with longer term maintenance of successful clinical outcome. 
Last but not least, it becomes apparent through the current periodontal 
literature that there is considerable variation between studies in the reported levels of 
RANKL, OPG or RANKL/OPG ratio levels (Table). Although there is as yet no 
stringent definition of the pathological concentrations of these measures in biological 
fluids, an early study in systemically healthy adults identified that the RANKL/OPG 
ratio in serum was 2.18 in men and 2.78 in women (Jung et al. 2002). However, at 
present there is no consensus in such values with regards to healthy and diseased 
periodontium. The need is raised to establish universal methodological and technical 
standards for the study of the RANKL-OPG system in the periodontium. In other 
terms, there is a requirement for globally standardised sample collection techniques 
and detection assays. The upper or lower limits of physiological RANKL and OPG 
concentrations in GCF, saliva and serum need to be defined and a "healthy-range" or 
"periodontitis-range" RANKL/OPG ratio should be deduced. 
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Clinical Relevance 
Scientific rationale for study: 
RANKL induces bone resorption, whereas OPG inhibits this action. This Review 
summarizes the current knowledge on the RANKL-OPG system in relation to Clinical 
Periodontology, discussing its diagnostic and prognostic value for periodontal 
diseases. 
Principal findings: 
Periodontitis is associated with increased RANKL and decreased OPG levels in 
gingival tissue and GCF, resulting in increased RANKL/OPG ratio. Smoking and 
diabetes mellitus further enhance this ratio. Conventional periodontal treatment may 
not affect this ratio. 
Practical implications: 
Although the RANKL/OPG ratio may have a potential as a biomarker for 
periodontitis, its predictive value for the on-going disease is unclear. Further adjunct 
treatment modalities may be required to decrease this ratio. 
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Table: Studies involving GCF concentrations of RANKL and OPG, and 
RANKL/OPG ratio levels in health and periodontal disease. 
 
Publication  Study popul.  RANKL (pg/µl)  OPG (pg/µl)  Ratio 
Mogi et al 2004  CP (n=132) ap. 30-180  ap. 50-110 ap. 1.0-1.7 
   Health (n=28)  ap. 30   ap. 350-450 ap. 0.1 
Vernal et al 2004 CP (n=20) 116.99 ± 83.04 N/A  N/A 
Health (n=12) 188.07 ± 103.40  N/A  N/A 
Lu et al 2006 * CP (n=20) 0 - 285.75   0-29.05  N/A 
Health (n=4) 0 - 45.16  9.67 - 40.7 N/A 
Bostanci et al 2007 CP (n=28) 370.7 ± 54.7  119.6 ± 14.4 3.19 ± 0.23 
AP (n=25) 387.5 ± 42.8   101.5± 10.2  3.81 ± 0.15 
Ging. (n=22)  9 ± 5.7   167.6 ± 20.6 0.05 ± 0.03 
Health (n=21) 6.8 ± 3.8          408.1 ± 36.6     0.017±0.008 
Mogi, Otogoto 2007 CP (n=66)  87.7 ± 16.2  N/A  N/A 
Health (n=19) 10.9 ± 2.8   N/A  N/A 
Sakellari et al 2008 * CP (n=35) 0.19 ±  0.04  N/A  N/A 
Health (n=38) 0.07 ± 0.17  N/A  N/A 
Silva et al 2008 CP (n=56)  
Active sites:  131.17 ± 35.1  N/A  N/A  
Inactive sites:  108.80 ± 18.9  N/A  N/A 
Buduneli et al 2009 CP (n=20) 
    Smokers: 0.44 ± 0.27  1.78 ± 1.9 0.25  
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Non-smokers 0.60 ± 0.46  2.40 ± 4.26 0.25 
Santos et al 2010 CP (n=38) 
Well controlled diabetics:  
ap. 100   ap. 40  ap. 2.5  
Poorly controlled diabetics:  
ap. 250  ap. 25  ap. 10  
Ribeiro et al 2011 CP (n=20) 86.2 ± 39.9  13.4 ± 12.5 12.3 ± 12.7 
CP diabetics (n=37) 
Well controlled diabetics:  
 222.8 ± 294.2  45.0 ± 66.6 5.3  
Poorly controlled diabetics:  
402.5 ± 286.5   50.6 ± 61.6 24.7 
Bostanci et al 2011 CP (n =14)  433 ± 269  51 ± 29 9.1 ± 3.5 
AP (n =13)  468 ± 580  71 ± 74  5.9 ± 1.4 
 
Table Legend: The Table shows the concentrations of RANKL, OPG and 
RANKL/OPG ratio in GCF from healthy individuals and patients with gingivitis, CP 
and AP, analyzed by ELISA in different studies. The studies marked with an asterisk 
(*) have measured the total amounts of either molecule in GCF (provided as pg/site, 
for 30 sec sampling), whereas the others have calibrated these values for the measured 
GCF volume per site (provided as pg/µl). Where the actual means or ranges are not 
provided in the respective papers, an approximation (ap.) of the values is given, based 
of the available Figures. In papers where periodontal treatment is involved, only the 
baseline levels are given. 
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Figure Legend 
Schematic representation of the action of the RANKL-OPG system. (A) RANKL is 
expressed as a membrane bound (or secreted) ligand by a number of cell types, such 
as osteoblasts, fibroblasts, bone marrow stromal cells, and activated T- and B-cells. 
When RANKL binds to its cognate RANK receptor on the surface of pre-osteoclasts 
(cells of the monocyte/ macrophage cell lineage), it triggers a number of intracellular 
processes that lead to their fusion and differentiation into multi-nucteated mature 
osteoclasts (process called “osteoclastogenesis”). On the tissue level, osteoclasts 
attach on the bone surface and subsequently resorb bone. (B) The action of RANKL 
can be blocked by its soluble decoy receptor OPG, which has structural homology to 
RANK. When OPG binds to RANKL, it prevents its further interaction with RANK, 
thus inhibiting all the down-stream molecular events that would lead to osteoclast 
differentiation and bone resorption. Hence, OPG is an inhibitor of bone resoprtion. 
